• Nem Talált Eredményt

18 eredmény a kulcsszóra: 'breast cancer'

Bevesszük a kanyart?
[Csath Magdolna: Bevesszük a kanyart? – Tudás-Érték-Jövő. Kairosz Kiadó, 2019, 231 oldal]

Ezeket (az alkalmazhatóság statisztikai módszerekkel történő vizsgálata után) használhatjuk a gazdasági szerkezet átalakulásának nyomon követésére, ugyanakkor ebben az

Protected

N/A

3
0
0
2022
ÖSSZEFOGLALÓ REFERÁTUMOK

tis in early breast cancer patients: effects of systemic treatments. és mtsai: Conformal adjuvant radiotherapy in breast cancer. és mtsa: Specialisation and breast

Protected

N/A

6
0
0
2022
Az ösztrogénmetabolom biológiai és klinikai jelentősége lokális folyamatokban

Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast

Protected

N/A

9
0
0
2022
ARTICLE IN PRESS

mAb, Monoclonal antibody; MCF-7, Michigan Cancer Foundation-7 breast-cancer cell line; MDA-MB-231, Breast-cancer cell line; NSCLC, Non-small cell lung cancer; OEC- M1, Human

Protected

N/A

8
0
0
2022
Comparative Constitutionalism in Central Europe – Summary

To provide a general overview on the constitutionalism of Central European Post-Socialist countries, the volume first goes through the constitutional history of the examined

Protected

N/A

7
0
0
2022
Gene expression based prognostic classification of  solid tumors

The topics are the gene expression based classification of colorectal cancer, new prognostic classification of breast cancer, prediction lymph node status of

Protected

N/A

14
0
0
2022
lnc00673 (ERRLR01) is a Prognostic Indicator ofOverall Survival in Breast Cancer

We analyzed Affymetrix U133 gene chip data, as well as the breast cancer TCGA dataset and determined that across four distinct breast cancer subtypes, as

Protected

N/A

21
0
0
2022
MAGYAR ONKOLÓGIA

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert C onsensus on the Primary Therapy of Early Breast Cancer. The

Protected

N/A

20
0
0
2022
Murine Breast Cancer Model

We show here that ASC.B6- derived factors induce Akt phosphorylation, hence switch on the PI3K/Akt signaling pathway, and thereby promote cell survival, proliferation, growth

Protected

N/A

8
0
0
2022
Journal of Breast Cancer

(A) An intracystic papillary component (right) is surrounded by a thick fibrous capsule and an invasive carcinoma (left) component on the low-power view of the lesion (H&E

Protected

N/A

4
0
0
2022
Progesteronereceptormembranecomponent1regulateslipidhomeostasisanddrivesoncogenicsignalingresultinginbreastcancerprogression RESEARCHARTICLEOpenAccess

Since lipid rafts play a role in breast cancer progression and due to the fact that (a) PGRMC1 overexpressing hormone receptor-positive breast cancer cells have higher amounts

Protected

N/A

16
0
0
2022
linc00673 (ERRLR01) is a prognostic indicator ofoverall survival in breast cancer

We analyzed Affymetrix U133 gene chip data, as well as the breast cancer TCGA data set and determined that across four distinct breast cancer subtypes, as determined by

Protected

N/A

14
0
0
2022
PSMB7 is associated with doxorubicin resistance and is a prognostic biomarker in breast cancer

In this study I examined the role of the proteasome subunit PSMB7 gene on drug resistance in a breast cancer cell line and in breast cancer patients. In a cell culture model

Protected

N/A

13
0
0
2022
Bone Homeostasis and Breast Cancer

Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy

Protected

N/A

10
0
0
2022
DOKTORI ÉRTEKEZÉS

Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost Partial Breast Irradiation using

Protected

N/A

117
0
0
2022
MTA DOKTORI ÉRTEKEZÉS TÉZISEIDóziseloszlások kvantitatív elemzése emlbrachyterápiás tűzdeléseinél: a Párizsképvezérelt, inverz optimalizálásig

Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost Partial Breast Irradiation using

Protected

N/A

33
0
0
2022
SEMMELWEIS EGYETEM DOKTORI ISKOLA Ph.D. értekezések 2403. KRENCZ ILDIKÓ

(2015) Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer,

Protected

N/A

138
0
0
2022
teljes körű és holisztikus szemléletű. Emlőrák: gondozás, rehabilitáció, pszichoonkológia

American Cancer Society/Amer- ican Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. Gradishar WJ, Anderson BO, Blair SL,

Protected

N/A

11
0
0
2022

Töltsön fel további dokumentumokat, és töltse le azonnal az anyagtanulmányokat!